A new drug to treat alcoholism has enhanced the chances of hard-drinking Japanese addicts quitting alcohol, it has been revealed.
While conventional drugs discourage drinking by causing unpleasant symptoms, such as palpitations, nausea and headaches, after alcohol consumption, new drug- Regtect- improves the chemical balance in the brain to suppress a patient's craving, the Japan Times reported.
Susumu Higuchi, director of the National Hospital Kurihama Alcoholism Center, hopes that the new drug will help Japanese drinkers quit alcohol.
Alcohol dependence is a mental disease that can cause serious health problems, including liver, pancreas and brain damage.
A clinical test of Regtect involving about 320 patients in Japan found that after 24 weeks of use, nearly half achieved abstinence, compared with 36 percent in the placebo group.
However, it does have some side effects, including diarrhea, which are considered as manageable.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
